Published in Pharmacogenetics on October 01, 1997
Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther (2013) 3.05
The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol (2001) 2.38
Evaluation of genetic factors for warfarin dose prediction. Clin Med Res (2007) 2.37
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol (2002) 1.28
Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol (2005) 1.16
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol (2002) 1.05
Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions. Eur J Clin Pharmacol (2004) 0.99
Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut (2003) 0.98
Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol (2007) 0.92
Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol (2010) 0.90
1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr Cardiol (2006) 0.87
Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87
Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genet Test Mol Biomarkers (2013) 0.86
Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol (2003) 0.83
Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum. Korean J Intern Med (2014) 0.83
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol (2008) 0.82
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol (2003) 0.82
The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost (2011) 0.82
Warfarin toxicity and individual variability-clinical case. Toxins (Basel) (2010) 0.82
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost (2012) 0.81
Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther (2015) 0.78
Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur J Clin Pharmacol (2005) 0.78
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug Metab Dispos (2015) 0.78
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics Proteomics Bioinformatics (2016) 0.76
Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator. Drug Metab Dispos (2011) 0.76
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry. Genes Chromosomes Cancer (2014) 0.76
Prevalence of clinically actionable genotypes and medication exposure of older adults in the community. Pharmgenomics Pers Med (2017) 0.75
Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metabol Personal Ther (2015) 0.75
The major human rhinovirus receptor is ICAM-1. Cell (1989) 7.81
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest (1997) 3.52
Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther (2013) 3.29
Drosophila Futsch/22C10 is a MAP1B-like protein required for dendritic and axonal development. Neuron (2000) 2.70
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol (1992) 2.41
Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos (1999) 2.18
Gamma oscillations and object processing in the infant brain. Science (2000) 2.14
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 1.93
Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest (1974) 1.85
The standardization of terminology for researchers in female pelvic floor disorders. Int Urogynecol J Pelvic Floor Dysfunct (2001) 1.82
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol (1998) 1.80
An invasive cleavage assay for direct quantitation of specific RNAs. Nat Biotechnol (2001) 1.79
Improved non-parametric statistical methods for the estimation of Michaelis-Menten kinetic parameters by the direct linear plot. Biochem J (1977) 1.75
Ferrocene-mediated enzyme electrode for amperometric determination of glucose. Anal Chem (1984) 1.75
Enzymatic degradation of heme. Oxygenative cleavage requiring cytochrome P-450. Biochemistry (1972) 1.71
ON THE EXACERBATION IN CHRONIC GLOMERULONEPHRITIS. J Clin Invest (1940) 1.70
Can we manage sport related concussion in children the same as in adults? Br J Sports Med (2004) 1.69
DIET AS A PROPHYLACTIC AGENT AGAINST PUERPERAL SEPSIS. Br Med J (1931) 1.64
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59
Nucleotide sequence of the alpha ribosomal protein operon of Escherichia coli. Nucleic Acids Res (1985) 1.58
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys (1996) 1.56
Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation (2000) 1.56
Development of an integrated laboratory information management system for the maize mapping project. Bioinformatics (2003) 1.50
Segmentation, attention and phenomenal visual objects. Cognition (2001) 1.44
N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J (1992) 1.43
Transcriptional regulation of a rat liver glutathione S-transferase Ya subunit gene. Analysis of the antioxidant response element and its activation by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem (1994) 1.42
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost (2007) 1.41
Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye (Lond) (1997) 1.41
Clinical management of allergic rhinitis - the Allergy Society of South Africa Consensus update. S Afr Med J (2006) 1.40
Maternal brain death and prolonged fetal survival. Obstet Gynecol (1989) 1.39
Tricyclic antidepressant fatality: postmortem tissue concentrations. J Toxicol Clin Toxicol (2001) 1.38
Autorepressor properties of the pi-initiation protein encoded by plasmid R6K. Nucleic Acids Res (1985) 1.38
ABRF-98SEQ: Evaluation of peptide sequencing at high sensitivity. J Biomol Tech (2000) 1.36
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther (1994) 1.36
Fetal respiratory distress causing CNS and inner ear hemorrhage. Laryngoscope (1978) 1.31
The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther (1992) 1.30
Evaluation of distribution-free confidence limits for enzyme kinetic parameters. J Theor Biol (1978) 1.27
Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J Lab Clin Med (1973) 1.27
A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res (1999) 1.26
Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem (1994) 1.25
Homologous amino acid sequences in enzymes mediating sequential metabolic reactions. J Biol Chem (1978) 1.24
Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther (1992) 1.23
Longitudinal study of predictive factors for periodontal disease and tooth loss. J Clin Periodontol (1999) 1.22
Serious perinatal complications of non-proteinuric hypertension: an international, multicentre, retrospective cohort study. J Obstet Gynaecol Can (2003) 1.22
Interactions between extracellular Borrelia burgdorferi proteins and non-Borrelia-directed immunoglobulin M antibodies. Infect Immun (1992) 1.22
Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther (1994) 1.22
Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation (2001) 1.21
Characterization of two isomers of 8'-hydroxyzearalenone and other derivatives of zearalenone. J Agric Food Chem (1975) 1.20
Retrograde intubation dacryocystorhinostomy for proximal and midcanalicular obstruction. Ophthalmology (1999) 1.19
Marcus Gunn syndrome. Eye (Lond) (2004) 1.19
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science (1987) 1.18
Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos (1996) 1.18
Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos (1996) 1.17
Investigation of opportunistic pathogens in municipal drinking water under different supply and treatment regimes. Water Sci Technol (2004) 1.17
Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem (2001) 1.15
Absolute configurations of the four warfarin alcohols. J Med Chem (1972) 1.15
The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther (1986) 1.14
Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos (2000) 1.13
Preattentive filling-in of visual surfaces in parietal extinction. Science (1997) 1.12
Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest (1970) 1.11
Role of cryptic receptors (cryptitopes) in bacterial adhesion to oral surfaces. Arch Oral Biol (1990) 1.11
Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos (2001) 1.10
Pulsed-spray pharmacomechanical thrombolysis: preliminary clinical results. AJR Am J Roentgenol (1989) 1.09
Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem (1994) 1.09
Infections caused by herpes simplex virus in the immunocompromised host: natural history and topical acyclovir therapy. J Infect Dis (1984) 1.09
Safety of hydrogel dressings. J Hum Lact (2001) 1.08
The formation of plasma membrane blebs in hepatocytes exposed to agents that increase cytosolic Ca2+ is mediated by the activation of a non-lysosomal proteolytic system. FEBS Lett (1986) 1.08
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos (1996) 1.06
Structure of human erythrocyte spectrin. II. The sequence of the alpha-I domain. J Biol Chem (1983) 1.05
Prediction of maximal oxygen consumption. Comparison of the Bruce and Balke treadmill protocols. Chest (1975) 1.05
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol (1998) 1.05
Evidence for the involvement of a specific cell wall layer in regulation of deep supercooling of xylem parenchyma. Plant Physiol (1989) 1.05
The natural history of pelvic organ support in pregnancy. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.04
A comparison of three maximal treadmill exercise protocols. J Appl Physiol (1974) 1.04
Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains. J Biol Chem (1997) 1.03
A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem (2000) 1.02
Contagious bovine pleuropneumonia: Serologic response of cattle after single and double vaccination with T-1 culture vaccine. Rev Elev Med Vet Pays Trop (1968) 1.02
B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J Immunol (1997) 1.02
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics (2001) 1.01
Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos (1999) 1.01
Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry (1999) 1.01
Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest (1980) 1.01
Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG (2007) 1.00
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther (2012) 1.00
Structure of human erythrocyte spectrin. I. Isolation of the alpha-I domain and its cyanogen bromide peptides. J Biol Chem (1983) 0.99
The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci (1971) 0.98
A comparison of the reproducibility and physiologic response to three maximal treadmill exercise protocols. Chest (1974) 0.98
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos (2001) 0.98
Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol (1994) 0.98
In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev (1993) 0.97
Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4'-dimethylbiphenyl by cytochrome P450: relationship between distance of methyl groups and masking of the intrinsic isotope effect. Biochemistry (1997) 0.97
Comparing regional transcript profiles from maize primary roots under well-watered and low water potential conditions. J Exp Bot (2006) 0.97
Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos (2000) 0.97